Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

nt of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... today announced that it will release its unaudited financial results ... on Tuesday, May 28, 2013.  The Company will host a ... EDT (May 28, 2013 at 8:00 p.m. China Standard Time) ... on recent corporate developments. To access the conference ...
(Date:5/16/2013)... , May 16, 2013  Nektar Therapeutics, (Nasdaq: ... W. Robin , is scheduled to present at the ... York at the Sheraton New York Hotel on ... The presentation will be accessible via a Webcast through ... of the Nektar website: http://www.nektar.com . This Webcast will ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... results from a Phase 1/2 study of perifosine in ... relapsed from or refractory to bortezomib , ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ... in combination with bortezomib (+/- dexamethasone) in patients with ...
... Survival in Patients with Poor Prognostic Factors , ... HealthCare Pharmaceuticals Inc. today announced results from three studies showing ... lymphocytic leukemia (CLL) patients who have poor prognostic indicators. These ... American Society of Hematology in San Francisco, California. , ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 As ... courts throughout the country, Bernstein Liebhard LLP notes that ... patients often suffer tissue damage before they experience any ... according to Science Daily will appear in the Journal ... recipients underwent MRI screens of their hips. The ...
(Date:5/18/2013)... May 18, 2013 The “Sleep Apnea ... Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal ... to 2017” analyzes and studies the major market drivers, ... Rest of the World. , Browse , ... 16 Figures , 318 pagesand ...
(Date:5/18/2013)... The Ayurvedic practitioner program will be offered in ... Program is available in Mexico via Live Internet or ... practiced for over 5,000 years. In Ayurvedic medicine ( ... when an individual lives in harmony with their environment, ... aims to heal an individual in all levels (physically, ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Losing weight remains ... But among the horde of new weight loss products available ... talked about. Recent studies about this newest weight loss supplement ... ideal body shape. , Garcinia Cambogia is a sub-tropical fruit ... tamarind. Eating the fruit can suppress a person’s appetite, while ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... Wake Forest University School of Medicine has reported in ... to the aorta which may occur due to bypass ... heart which may lead to cognitive loss and the ... to the aorta reduces development of cognitive defects. ...
... wristwatch invented by South Africa's Gervan Lubbe which can detect ... hazard. They have warned that the device may contribute towards ... also expressed doubts if the watch can really perform functions ... a potential public health threat as opposed to a boon ...
... four Marlboro smokers for hi-tech screenings aimed at the early detection ... pay for spiral CT scans which is estimated at ?300. //If ... save several thousand lives as a result of early detection. The ... smoking. ,A class action status is sought by ...
... International study conducted by the University of New South ... the HIV treatment can be life threatening and resulted ... because //they identified that the patients who took a ... progression of the disease, compared with those who took ...
... teenage smokers in Alberta in 2005, when in comparison to 2004. ... are being blamed for this by anti-smoking campaigners. The young adult ... the Alberta Alcohol and Drug Abuse Commission for this state of ... of Alberta who belong to the age group of 15 years ...
... the Health Minister on the prescription issue. Under this nurses ... move has been widely criticized, but the BMA's GP committee ... statement of the Health Minister on the introduction of nurse ... who should be able to spend more time with those ...
Cached Medicine News:Health News:Breaks In The HIV Treatment Resulted In Devastating Results. 2
... The MultiBlot tray is specifically designed ... commonly used 10.16 x 13.34cm dot blot ... exterior dimensions as a standard microplate for ... and accepts commercially available dot blot membranes ...
... offers rapid and effective transfers over ... blotting area. Designed for use with ... used with the PROTEAN Plus Dodeca ... provides uniform transfers in as little ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
... regulator. The Model 785 vacuum blotter ... from an agarose gel onto a nylon ... min for transfer, the nucleic acid samples ... to a membrane, and the hybridization reaction ...
Medicine Products: